GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Impact of the Specific Endothelin A Receptor Antagonist ZD4054 on Overall Survival and Bone Metastasis in Patients with Hormone-Resistant Prostate Cancer: Results of a Phase II Trial
SAN FRANCISCO, CA (UroToday.com) - Dr. Dawson discussed ZD4054, an endothelin A receptor antagonist. Endothelin A promotes angiogenesis, osteoblast stimulation and disease progression.
 | Written by Christopher P. Evans, MD, a Contributing Editor with UroToday. |
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |
